IN2013MU01224A - - Google Patents

Info

Publication number
IN2013MU01224A
IN2013MU01224A IN1224MU2013A IN2013MU01224A IN 2013MU01224 A IN2013MU01224 A IN 2013MU01224A IN 1224MU2013 A IN1224MU2013 A IN 1224MU2013A IN 2013MU01224 A IN2013MU01224 A IN 2013MU01224A
Authority
IN
India
Prior art keywords
compositions
sitagliptin
metformin
salts
present
Prior art date
Application number
Other languages
English (en)
Inventor
Girish Kumar Jain
Venkataramana Naidu
Atul Patil
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to US14/766,939 priority Critical patent/US20150366863A1/en
Priority to EP14722341.6A priority patent/EP2996680A1/en
Priority to PCT/IB2014/060081 priority patent/WO2014170770A1/en
Priority to IN1224MU2013 priority patent/IN2013MU01224A/en
Publication of IN2013MU01224A publication Critical patent/IN2013MU01224A/en
Priority to ZA2015/05916A priority patent/ZA201505916B/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN1224MU2013 2013-03-28 2014-03-24 IN2013MU01224A (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US14/766,939 US20150366863A1 (en) 2013-03-28 2014-03-24 Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
EP14722341.6A EP2996680A1 (en) 2013-03-28 2014-03-24 Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
PCT/IB2014/060081 WO2014170770A1 (en) 2013-03-28 2014-03-24 Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
IN1224MU2013 IN2013MU01224A (es) 2013-03-28 2014-03-24
ZA2015/05916A ZA201505916B (en) 2013-03-28 2015-08-17 Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1224MU2013 IN2013MU01224A (es) 2013-03-28 2014-03-24

Publications (1)

Publication Number Publication Date
IN2013MU01224A true IN2013MU01224A (es) 2015-04-17

Family

ID=54395595

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1224MU2013 IN2013MU01224A (es) 2013-03-28 2014-03-24

Country Status (1)

Country Link
IN (1) IN2013MU01224A (es)

Similar Documents

Publication Publication Date Title
PH12021550792A1 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
PH12016501581A1 (en) Benzimidazol-2-amines as midh1 inhibitors
PH12016501807A1 (en) Novel compounds
TN2017000258A1 (en) Pyrazolopyridinamines as mknk1 and mknk2 inhibitors
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
PH12014502065A1 (en) Vesicular formulations
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
MX2016014261A (es) Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis.
IN2013MU03428A (es)
IN2013MU01224A (es)
IN2013MU01222A (es)
IN2013MU01225A (es)
IN2013MU01223A (es)
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
IN2013MU03427A (es)
IN2014DN10683A (es)
IN2013MU01158A (es)
IN2013MU01159A (es)
MA39762A (fr) Nouveaux composés
NZ764041A (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis